Skip to main content
. 2022 Dec 23;13:1037214. doi: 10.3389/fimmu.2022.1037214

Figure 1.

Figure 1

Study design illustrating patient cohorts and the time course of performed analyses. BL, baseline; DMT, disease modifying therapy; HC, controls without MS; IFN, interferon; Ig, immunoglobulin; MS, multiple sclerosis; N, nucleocapsid; NAT, natalizumab; OCR, ocrelizumab; pwMS, patients with MS; pv2/3/4, post second/third/fourth vaccination; S, spike; SARS-CoV-2, severe acute respiratory syndrome; S1P, sphingosine 1-phosphate receptor modulator; V, visit; vacc, vaccination; w/o, without. Created with BioRender.com.